CLS and ClearPoint Neuro partner with Dartmouth Health on a $2.98 million NIH-funded study to validate MR-guided laser therapy for spinal metastases.
Clinical Laserthermia Systems (CLS) has been selected as an industry partner for a five-year, $2.98 million NIH-funded research program led by Dartmouth Health. This collaboration allows CLS to leverage its existing neuro laser therapy technology, previously used for brain procedures, to address the significant clinical need for minimally invasive treatment of spinal metastases.
To advance MR-guided laser interstitial thermal therapy (LITT) for patients suffering from spinal metastases.
The program is supported by the U.S. National Cancer Institute (NCI) with a $2.98 million R01 award.
ClearPoint Neuro is a key industry partner in the NCI-funded research program, which utilizes the company's Prism Neuro Laser Therapy System for spinal metastases treatment. This partnership validates the utility of the Prism system in new clinical domains, potentially driving future adoption and market expansion for the platform.
The research utilizes the ClearPoint Prism Neuro Laser Therapy System.
It offers a less invasive alternative to conventional surgery, which is often associated with high blood loss, prolonged hospitalization, and wound complications.
Clinical Laserthermia Systems and ClearPoint Neuro have secured a role in a five-year, $2.98 million National Cancer Institute research program. The collaboration focuses on advancing MR-guided laser interstitial thermal therapy for spinal metastases, leveraging the ClearPoint Prism Neuro Laser Therapy System to improve patient outcomes.
The collaboration aims to advance MR-guided laser interstitial thermal therapy (LITT) for treating spinal metastases, moving from pre-clinical validation toward clinical evaluation.